|By Marketwire .||
|February 7, 2013 06:19 AM EST||
SOPHIA ANTIPOLIS, FRANCE -- (Marketwire) -- 02/07/13 --
Nicox to present at the 15(th) Annual BIO CEO & Investor Conference
Nicox S.A. (EURONEXT PARIS: COX), a new international player in the ophthalmic market, today announced that Michele Garufi, Chairman and CEO, will be presenting at the 15th Annual BIO CEO & Investor Conference in New York, NY, on Tuesday February 12(th) at 3:30pm EST.
Michele Garufi will give an overview of the Company's growth strategy and will highlight the corporate milestones and business development opportunities of Nicox.
Michele Garufi will also be available for one-on-one meetings at the conference.
The presentation will be uploaded on Nicox website www.nicox.com on Wednesday February 13(th). No live audio broadcast or archived recording will be available.
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new mid-sized international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, the Nicox team is focused on developing and marketing novel pharmaceuticals and diagnostic devices that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus, a test for the differential diagnosis of acute conjunctivitis in-licensed from RPS®.
The Company's pipeline includes latanoprostene bunod, a novel drug-candidate based on Nicox's proprietary nitric oxide (NO)- donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in non-ophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada) and Ferrer.
Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Small Caps). For more information please visit www.nicox.com.
This communication may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements.
Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2011 » filed with the French Autorité des Marchés Financiers (AMF) on February 29, 2012 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).
Nicox S.A. Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia Antipolis | 06560 Valbonne | France T: +33 (0)4 97 24 53 00 | F: +33 (0)4 97 24 53 99
Nicox to present at the 15th Annual BIO CEO & Investor Conference:
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE
Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00
D+44 (0)20 7269 7205
M +44 (0) 7515 597 858
D +44 (0)20 3077 0458
M +44 (0) 7843 080947